$53.12
+0.80 (+1.53%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where EXEL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
55 interventional · 1 expanded access · 15 with posted results
Held by 16 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, +11 more) · FINRA short interest 13.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Enrolling by invitation | Drug: Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer | 5,000 | 2030-05-31 | in 1,381 d | 2026-08-18 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseNCT07750158Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the InvestigatorRandomized · Triple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Zanzalintinib, Placebo · Biological: MK-34574 | Colorectal Cancer | 600 | 2030-04-05 | in 1,325 d | 2026-08-06 |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Zanzalintinib, Everolimus | Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | 440 | 2029-06-30 | in 1,046 d | 2026-08-07 |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsNCT05932862Dose Escalation Stage: Incidence of TEAEs and SAEs; AEs Leading to Dose Modification, Discontinuation, or Death; and Laboratory AbnormalitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: XL309, Olaparib | Advanced Solid Tumor | 429 | 2029-01-03 | in 868 d | 2025-09-05 |
| Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Zanzalintinib, Zanzalintinib-matched Placebo · Biological: Pembrolizumab | Head and Neck Squamous Cell Carcinoma | 600 | Aug 2028 | ≤ 743 d | 2025-08-17 |
| Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNCT07773454Number of Participants With Dose-Limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: Zanzalintinib | Cancer, Pediatric Cancer | 18 | 2028-07-31 | in 712 d | 2026-08-19 |
| A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaNCT07428616Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR)Open-label · Treatment | Phase 2 | Recruiting | Drug: Zanzalintinib | Meningioma | 100 | 2028-02-29 | in 559 d | 2026-07-27 |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid TumorsNCT07123103Number of Participants with a Dose-limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: XB371 | Solid Tumors | 150 | Nov 2027 | ≤ 468 d | 2026-02-17 |
| A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid TumorsNCT06952010Dose Escalation Cohort: Number of Participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: XB628 · Drug: Zanzalintinib | Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor | 303 | 2027-05-31 | in 285 d | 2026-06-24 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2027-01-31 | in 165 d | 2026-08-05 |
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: XL092, Nivolumab, Sunitinib Malate | Non-Clear Cell Renal Cell Carcinoma | 317 | 2026-12-15 | in 118 d | 2026-07-29 |
| Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: XB010, Pembrolizumab | Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC) | 396 | 2026-11-23 | in 96 d | 2026-06-22 |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: XL092, Atezolizumab, Avelumab | Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer | 325 | 2026-08-31 | in 12 d | 2024-11-19 |
| Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized ParticipantsRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: XL092, Atezolizumab, Regorafenib | Colorectal Cancer | 901 | 2026-06-16actual | — | 2026-07-17 |
| Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)NCT06962332Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time t Corresponding to the Last Quantifiable Concentration (AUC0-t) of ZanzalintinibNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Zanzalintinib | Hepatic Impairment, Moderate Hepatic Impairment | 20 | Dec 2025 | — | 2025-06-22 |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117results2025-12-18Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone | Metastatic Prostate Cancer, Prostate Adenocarcinoma | 575 | 2024-04-19actual | — | 2025-12-18 |
| Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended DoseNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2023-02-21actual | — | 2025-08-17 |
| Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219results2025-09-10Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Cabozantinib, Cabozantinib-matched placebo · Biological: Nivolumab, Ipilimumab | Renal Cell Carcinoma | 855 | 2022-01-31actual | — | 2025-09-10 |
| Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791results2025-12-11Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) PopulationRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Cabozantinib, Cabozantinib, Sorafenib, Atezolizumab | Hepatocellular Carcinoma | 837 | 2021-11-30actual | — | 2025-12-11 |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388results2023-05-18Progression Free Survival (PFS)Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Cabozantinib, Placebo | Differentiated Thyroid Cancer | 187 | 2020-08-19actual | — | 2025-09-25 |
| A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerNCT01896479results2025-09-02Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Active, not recruiting | Drug: Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg, Placebo tablet, Placebo capsule | Medullary Thyroid Cancer | 247 | 2020-07-15actual | — | 2025-09-02 |
| Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)NCT06191796Dose-finding Stage: Number of participants with dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated prior to starting the Phase 2 portion due to a business decision. | Drug: zanzalintinib, AB521 · Biological: Nivolumab | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | 25 | 2025-05-12actual | — | 2025-06-12 |
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid TumorsNCT06630247Dose-escalation and Dose-finding Stages: Number of Participants with Treatment-Emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: XL495, ADC cytotoxic agents | Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis | 9 | 2025-05-07actual | — | 2025-06-25 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284Dose-Escalation Stage: MTD/recommended dose for XB002Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: XB002, Nivolumab, Bevacizumab | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors | 269 | 2025-03-10actual | — | 2025-04-04 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)NCT04726332Dose-Escalation Stage: MTD/recommended dose for XL102Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business reasons | Drug: XL102, Fulvestrant, Abiraterone, Prednisone | Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer | 52 | 2024-05-02actual | — | 2024-05-14 |
| Study of XL114 in Subjects With Non-Hodgkin's LymphomaNCT05144347Dose-Escalation Stage: Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD) for XL114Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Due to Sponsor reasons. | Drug: XL114 | Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 2 | 2022-11-01actual | — | 2023-07-11 |
| Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior SorafenibNCT01908426results2019-03-01Overall Survival (OS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Cabozantinib tablets, Placebo tablets | Hepatocellular Carcinoma | 707 | 2017-10-16actual | — | 2021-05-06 |
| Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced CancerNCT01553656Maximum Tolerated Dose (MTD) and Recommended Phase 2 DoseOpen-label · Treatment | Phase 1 | Completed | Drug: cabozantinib capsules, cabozantinib tablets | Solid Tumors, Cancer, NSCLC | 85 | May 2015actual | — | 2015-08-20 |
| A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell CarcinomaNCT01865747results2017-07-18Progression-free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Cabozantinib tablets, Everolimus (Afinitor) tablets | Renal Cell Carcinoma | 658 | 2015-05-22actual | — | 2021-04-27 |
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058results2026-01-08Radiographic Progression Free Survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decided to close the study prior to completion of enrollment. This was a business decision and not based on the safety results of the study. | Drug: cabozantinib, abiraterone, prednisone | Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms | 54 | Nov 2014actual | — | 2026-01-08 |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerNCT01522443results2018-05-23Pain Response at Week 6 Confirmed at Week 12, Week 12 ReportedRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307. | Drug: cabozantinib, mitoxantrone, prednisone | Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms | 119 | Oct 2014actual | — | 2018-05-23 |
| Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100NCT01605227results2018-03-14Overall Survival (OS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: cabozantinib, prednisone | Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms | 1,028 | Sep 2014actual | — | 2018-03-14 |
| Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult SubjectsNCT01493869AUC, Cmax, tmax, t1/2, CL/F, and V/F parameters as a measure of the PK of a single oral 75 mg dose of cabozantinib in hepatic impaired adult subjects compared to healthy adult subjects matched for age, gender, body mass index (BMI), and ethnicityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: cabozantinib | Healthy, Hepatic Impairment | 26 | May 2014actual | — | 2014-09-22 |
| Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225results2024-04-25Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort OnlyRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Cabozantinib, Placebo | Solid Tumors, Cancer | 730 | May 2013actual | — | 2024-04-25 |
| A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal FunctionNCT01761773PharmacokineticsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: cabozantinib | Healthy, Renal Impairment | 32 | Apr 2013actual | — | 2014-09-22 |
| Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaNCT00960492Evaluate the safety and tolerability of oral administration of XL184 added to first-line treatment for subjects with newly diagnosed GBNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: XL184, temozolomide, temozolomide, temozolomide · Radiation: Radiation Therapy | Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma | 26 | Nov 2012actual | — | 2014-09-22 |
| A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid TumorsNCT01100619Pharmacokinetics of XL184 and rosiglitazoneOpen-label · Treatment | Phase 1 | Completed | Drug: rosiglitazone, XL184 | Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma | 40 | Aug 2012actual | — | 2013-09-19 |
| A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)NCT00596648results2026-01-13Phase 1: Duration of Exposure of Cabozantinib With ErlotinibRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: XL184, erlotinib | Carcinoma, Non-Small-Cell Lung | 92 | 2012-08-02actual | — | 2026-01-13 |
| Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288results2024-02-05Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: XL184 | Glioblastoma Multiforme | 222 | Jun 2012actual | — | 2024-02-05 |
| Study of XL281 in Adults With Solid TumorsNCT00451880Safety, tolerability, and maximum tolerated dose (MTD) of once daily or twice daily oral administration of XL281Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: XL281, famotidine | Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma | 180 | Oct 2011actual | — | 2011-10-13 |
| Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid CancerNCT00704730results2014-09-09Progression-Free Survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: XL184, Placebo | Thyroid Cancer | 330 | Oct 2011actual | — | 2021-04-20 |
| Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseNCT01068782results2026-02-25Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed. | Drug: Cabozantinib | Astrocytic Tumors | 19 | May 2011actual | — | 2026-02-25 |
| Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesNCT00215605Safety, tolerability, maximum tolerated dose (MTD), and dose-limiting toxicity of oral administration of XL184Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: XL184 | Lymphoma, Cancer, Thyroid Carcinoma | 85 | Apr 2011actual | — | 2013-02-27 |
| Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic LeukemiaNCT00464113Safety, tolerability, and maximum tolerated dose of once-weekly and/or twice-weekly 1-hour intravenous (IV) infusion of XL228Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: XL228 | Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | 49 | Dec 2010actual | — | 2015-08-21 |
| Study of XL228 Administered Intravenously to Subjects With Advanced MalignanciesNCT00526838To assess the safety and tolerability of XL228 administered as a once-weekly or twice-weekly 1-hour intravenous (IV) infusion in subjects with advanced malignancies.Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: XL228 | Cancer, Lymphoma | 84 | Dec 2010actual | — | 2015-08-21 |
| Safety Study of Pharmacokinetics of XL888 in Adults With Solid TumorsNCT00796484Safety, tolerability, and maximum tolerated dose of oral administration of XL888 when administered on an intermittent schedule to adults with solid tumorsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: XL888 | Cancer | 33 | Nov 2010actual | — | 2015-08-21 |
| Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsNCT00704392Safety, tolerability, and maximum tolerated dose (MTD) of XL647 administered in combination with XL147 orally dailyOpen-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Study not initiated | Drug: XL647, XL147 | Cancer, Non-small-cell Lung Cancer, Breast Cancer | 0 | Dec 2009 | — | 2015-08-20 |
| A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or SunitinibNCT00570635Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ≥16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinibRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: XL820, XL820 | Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms | 16 | May 2009actual | — | 2013-06-07 |
| A Phase 1 Study of XL019 in Adults With Polycythemia VeraNCT00595829Safety and tolerability of XL019 as a single agent when orally administered in adults with Polycythemia Vera (PV)Non-randomized · Open-label · Treatment | Phase 1 | Terminated | Drug: XL019 | Polycythemia Vera | 3 | Feb 2009actual | — | 2015-08-21 |
| A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced MalignanciesNCT00475917Safety and tolerability of XL844 as a single agent and in combination with gemcitabine when administered orally to subjects with advanced malignanciesNon-randomized · Open-label · Treatment | Phase 1 | Terminated | Drug: XL844, Gemcitabine | Cancer, Lymphoma | 28 | Dec 2008actual | — | 2015-08-21 |
| Study of XL820 in Adults With Solid TumorsNCT00129571Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: XL820 | Cancer | — | — | — | 2008-06-04 |
| Safety Study of XL844 in Subjects With Chronic Lymphocytic LeukemiaNCT00234481Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study closed due to slow enrollment | Drug: XL844 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | — | — | — | 2008-06-04 |
| Study of XL820 Given Orally Daily to Subjects With Solid TumorsNCT00350831maximum tolerated doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: XL820 | Cancer | 30 | — | — | 2008-08-18 |
| Study of XL418 in Adults With Solid TumorsNCT00460278Safety, tolerability, and maximum tolerated dose of XL418 with daily oral administrationNon-randomized · Open-label · Treatment | Phase 1 | Suspendedsponsor's stated reason: Enrollment suspended due to low drug exposure. | Drug: XL418 | Cancer, Solid Tumors | 63 | — | — | 2008-06-04 |
| A Safety Study of XL019 in Adults With MyelofibrosisNCT00522574To evaluate the safety, tolerability, maximum tolerated dose, and dose-limiting toxicities of XL019 as a single agent when orally administered in subjects with PMF, post-PV MF, or post-ET MF.Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Due to emerging safety data | Drug: XL019 | Myeloproliferative Disorders, Myelofibrosis, Polycythemia Vera, Thrombocythemia, Essential | 100 | — | — | 2011-04-05 |
| Expanded Access of Cabozantinib in Medullary Thyroid CancerNCT01683110expanded access | — | Approved for marketing | Drug: cabozantinib | Medullary Thyroid Cancer | — | — | — | 2013-01-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19